A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

Inclusion Criteria

• •1. The subject has a histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective, and there are no therapies known to prolong survival.
• •2. The subject has disease that is assessable by tumor marker, physical, or radiologic means.
• •3. The subject is ≥18 years old.
• •4. The subject has an ECOG (Eastern Cooperative Oncology Group) performance status of ≤2.
• •5. The subject has adequate organ and marrow function.
• •6. The subject has the capability of understanding the informed consent document and has signed the informed consent document.
• •7. Sexually active subjects (male and female) must use medically acceptable methods of contraception during the course of the study.
• •8. Female subjects of childbearing potential must have a negative pregnancy test at screening.
• •9. If a subject has received more than three prior regimens of cytotoxic chemotherapy, more than two biologic regimens, or more than 3000 cGy to \>25% of his or her bone marrow, the investigator must discuss with the sponsor regarding subject suitability before enrollment.
• •10. The subject has had no other diagnosis of malignancy (unless non-melanoma skin cancer, in situ carcinoma of the cervix, or a malignancy diagnosed ≥5 years ago, and has had no evidence of disease for 5 years prior to screening for this study).